ERBB3 and ovarian carcinoma: Our data indicate a potential benefit of dual IGF-1R/ErbB3 inhibition for ovarian cancer treatment, and highlight the potential impact of istiratumab in combination with standard of care chemotherapy to treat ovarian cancer.